Best Stocks Under $5 Right Now → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Written by MarketBeat StaffUpdated July 19, 2022What Are Penny Stocks?Should Investors Buy Stocks Under $5?What Are the Rewards of Buying Stocks Under $5?What Are the Risks of Buying Stocks Under $5?How to Trade Stocks Under $5?What Are the Best Stocks Under $5?Like any group of stocks, penny stocks require discerning between price and value There is a primal attraction to stocks priced under $5. These stocks are also known as penny stocks. Some purists will suggest that penny stocks have to trade for less than $1. However, in recent years, investors generally accept the definition that any stock that consistently trades below $5 fits into the category of penny stocks. In this article, we’ll explain why stocks under $5 are considered penny stocks and whether investors should invest in penny stocks at all. We’ll also outline some of the risks and the rewards of buying stocks under $5. And we’ll provide some tips for successfully trading these stocks. What Are Penny Stocks? As mentioned above, penny stocks are stocks that trade for $5 or less. This definition means there are many options for investors including dollar stocks, penny stocks, and stocks that sell for fractions of one penny. One stereotype about penny stocks is that every company is a startup that is in a risky market sector. However, there are many established businesses trading on standard exchanges that trade for less than $5 per share. When these companies appear on major exchanges, they are viewed as carrying less risk because they have to meet regulatory requirements that keep their accounting transparent. That being said, penny stocks are usually small-cap companies (i.e. those with a market capitalization of less than $2 billion) that are either new to the market or undervalued and not recognized by investors. There tend to be fewer shares of these stocks available, meaning there is usually a wider spread between bids and asking prices. And because penny stocks are generally considered to be speculative investments, they carry a certain element of risk. But it’s this risk that provides the opportunity for investors to make significant gains. Should Investors Buy Stocks Under $5? A broader question might be, “Should you buy stocks at all?” The answer to both questions is the same: It depends. You should not buy stocks if you don’t have a discriminating sense of how to invest money, or if you don’t have guidance around the topic from someone who does. With the right knowledge, stocks are an excellent investment, and according to some estimates, far more sound than real estate. Yes, stock prices do fluctuate (sometimes wildly), but over the last several decades, they have outperformed real estate in some regards. And investors who know what they’re doing with stocks can make huge gains, build enormous wealth, and create exponential financial success. Stocks under $5, in particular, present an incredible opportunity to make huge gains. It all comes down to research. You never want to sink all of your investment cash into just one basket. Estimates vary on the exact percentage, but most experts agree that the majority of your portfolio should be invested in solid, stable companies. That said, stocks under $5 can be a good place to do a little value investing and give some growth to your cash. It’s important to keep in mind that there are many trading strategies in relation to the stock market, and investing in undervalued, up-and-coming companies is only one strategy. For example, some investors prefer to focus on stocks that pay out dividends, where each share pays out dividend payments of company profit—and a large number of shares creates a solid cash flow. Other investors like to buy shares in specific industries, like tech stocks, or they may choose to ride the market as they engage in the ups and downs of day trading, flipping stocks for profit. Whichever stock trading strategy you prefer, penny stocks can be some of the best growth stocks for their undervalued cost—if you trade the right way. What Are the Rewards of Buying Stocks Under $5? As mentioned, penny stocks present huge opportunities for growth. Take True Religion as an example—an apparel company based in Vancouver, Canada. This designer-jeans outfit was trading for $0.67 per share in July of 2004. Just nine years later, TowerBrook Capital Partners acquired the company and paid $32 for every share...a whopping 4676% profit. Can you think of any “normal stocks” that offered investors the same gains? They’re few and far between (though they do exist). These are the types of profit margins that traders dream of earning. Another advantage of penny stocks is that they can be an easy way for small-time investors to enter the market. You don’t necessarily have to sink everything into some sort of risky biotech company. There are plenty of brand-name companies that are trading at under $5. Purchasing shares of these recognized businesses could be your chance to enter the stock market in an affordable way—and cash out big if things work out. It’s not just about price, but about volume: A $500 investment might only buy you 5-10 shares of a recognizable blue-chip stock or it could buy you 100+ shares of a stock priced at $5 and below. If that company grows and becomes a mid-cap stock, you’ll see a lot more profit than you would have by investing in a more “normal” stock. For that very same reason, penny stocks may allow you to diversify your holdings to a greater extent, with less money (if you want to eschew mutual funds and pick stocks yourself). With just $100 in the market, you could buy ten shares of stock in ten different industries. What Are the Risks of Buying Stocks Under $5? Many stocks under $5 are companies that may be startups or riskier business ventures. One of the biggest examples is biotech, an industry with larger startup costs and huge risks for investors. A startup company may discover the cure for cancer, in which case, you can cash out as a billionaire. Or, they may not, and they’ll take all your money with them when they fold. Another disadvantage to stocks under $5 is that they may be stocks of a company that’s about to go bankrupt. They could be desperately selling shares of stock to raise money, or to help their executives bail out with a parachute built from your investment. Newly formed startups may also be on the verge of bankruptcy, and because of their lack of established history, no one may even know. Occasionally penny stocks will be part of a “pump and dump” scam, where investors build excitement over a particular stock to drive up the price. They may “leak” information that a startup energy company struck gold or put forth an imaginative but enticing earnings estimate for the next quarter. As the stock value climbs out of control (far beyond the actual value of the market cap), hoodwinked investors pour their dollars into the company. Then it crashes, and the only ones who benefit are the scammers who bought into the stock before they made it popular. Another more prosaic risk of stocks under $5 is that they may just not go anywhere, hovering under $5 for years on end. While this is certainly better than losing all your money, it’s not so conducive to portfolio growth. Yet another disadvantage to stocks under $5 is their low trading volume. They can be harder to unload if you need to, because you may not find a willing buyer. Moreover, many penny stocks of younger upstart companies will most likely not pay out dividends. You are only purchasing the stock to leverage a change in its price—or hoping that in the future they will play into your dividend investing strategy. As you can see, there are some risks and volatility associated with stocks under $5. However, it once again all comes down to playing it smart and doing your research. There are plenty of resources which will tell you about the most volatile stocks, along with providing stats to gauge their future possibilities. If you have a good head for what’s going on, you won’t fall for scams or pour all your money into a pipe dream. The best traders know which stocks to watch; they understand the ins and outs of dividend yield and market capitalization—and can leverage these stats into higher amounts of revenue. There’s no secret to what they’re doing. They’re actively learning and keeping their eyes on the best times to buy stocks at 52 week low points. They know when to hold their assets, and when to sell them. How to Trade Stocks Under $5? Some stocks under $5 are traded on the New York Stock Exchange and NASDAQ. However, most stocks under $5 trade through over the counter transactions (OTC). Everything about these OTC transactions is done electronically through the OTC Bulletin Board (OTCBB). Companies that are traded on the OTCBB must still meet requirements from the SEC and FINRA. However, these companies don’t meet the requirements for trading on a larger market. There are still more stocks under $5 that don’t even meet the requirements to be traded on the OTCBB. These stocks can be found on a listing service called Pink Sheets (so named because the stocks were once listed on pink sheets of paper). These companies are too small to be listed on a national exchange, or may not wish to make their accounting statements public—which means they don’t have to file with the SEC, and can’t be listed on a publicly-traded market. As you might expect, these Pink Sheet stocks can carry significant risks. They can be difficult to analyze because of the lack of transparency around their business; investors should use caution and due diligence when purchasing them. What Are the Best Stocks Under $5? Now that we’ve reviewed the pros and cons of stocks under $5 and explained how they work, let’s address the question that every investor wants to know: how do I actualize this information? It can be hard to find good stocks under $5, particularly in bull markets. This is a time when stocks frequently hit new all-time highs, and the price-to-earnings ratios of most S&P 500 companies make purchasing shares look like an expensive proposition. For these and other reasons, many investors have trouble finding low-priced stocks that haven't already appreciated greatly. In more normal markets, a typical S&P 500 company trades at about fifteen times their earnings. However, value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $5 requires investors to look at smaller and riskier companies in sectors that are either undiscovered or unrecognized by the market as a whole. When looking at cheap stocks to buy, some of them may not look especially attractive today, but long-term investors will recognize profit if they are willing to exercise patience and hold onto shares of these companies through multiple economic cycles. Some of these companies are solid investing ideas because they are small. As a result, they’re considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unrecognized or untested areas of the market. You may find even find crypto stocks, marijuana stocks, and bitcoin stocks on this list. Others have been beaten up by Mr. Market after a long period of slowing profits but are now actively trying to turn around their business and bounce back. This low-priced list of stocks showcases a lot of different industries, but these picks all carry two common characteristics: They all have a super-low share price of $5.00 or less, and they all consistently receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. 5G Stocks: The Path Forward is ProfitableEnter your email address below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. You will also receive our free daily email newsletter with the latest buy and sell recommendations from Wall Street's top analysts. Top Headlines and OffersDefense Contractor Stocks Explained, Plus Investment GuideMarch 14, 2024 1:36 PMView Defense Contractor Stocks Explained, Plus Investment Guide$5 Billion Boost for Taiwan Semiconductor Aids Nvidia ExpansionMarch 14, 2024 7:39 AMView $5 Billion Boost for Taiwan Semiconductor Aids Nvidia ExpansionCentral Bank Gold Heist In ProgressFrom Colonial Metals(Ad)View Central Bank Gold Heist In Progress4 Oversold Large Cap Stocks Yielding High DividendsMarch 14, 2024 6:30 AMView 4 Oversold Large Cap Stocks Yielding High DividendsActive Rebound: 2 Discrete Semiconductor Stocks Making MovesMarch 12, 2024 8:00 AMView Active Rebound: 2 Discrete Semiconductor Stocks Making MovesIs it Time to Buy These 5 Oversold Stocks?March 15, 2024 7:12 AMView Is it Time to Buy These 5 Oversold Stocks?Urgent new message from Porter StansberryFrom Porter & Company(Ad)View Urgent new message from Porter StansberryOracle's AI Cloud Demand Fuels Profitability SurgeMarch 14, 2024 1:17 PMView Oracle's AI Cloud Demand Fuels Profitability SurgeUnlock the Secrets: Navigate the Crypto vs. Stocks Investing MazeMarch 14, 2024 12:39 PMView Unlock the Secrets: Navigate the Crypto vs. Stocks Investing MazeIs it Time to Buy These 3 Underperforming Magnificent Seven Members?March 13, 2024 6:20 AMView Is it Time to Buy These 3 Underperforming Magnificent Seven Members?3 Large-Cap Stocks Buying Back Shares AggressivelyMarch 18, 2024 6:15 AMView 3 Large-Cap Stocks Buying Back Shares AggressivelyUnlock the Potential: Smart Strategies to Invest in CybersecurityMarch 15, 2024 10:01 AMView Unlock the Potential: Smart Strategies to Invest in CybersecurityAll Headlines Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Clean Energy FuelsNASDAQ:CLNEStock Price: $2.51 (-$0.01)P/E Ratio: -5.70Market Cap: $562.56 millionAverage Trading Volume: 1.74 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.80 (170.9% Upside)Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Zura BioNASDAQ:ZURAStock Price: $3.13 (-$0.06)Market Cap: $137.47 millionAverage Trading Volume: 78,377 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.60 (430.4% Upside)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.#3 - Integra ResourcesNYSEAMERICAN:ITRGStock Price: $0.74 (-$0.02)P/E Ratio: -1.15Market Cap: $52.35 millionAverage Trading Volume: 171,300 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.75 (408.8% Upside)Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.#4 - K92 MiningOTCMKTS:KNTNFStock Price: $4.70 (-$0.06)Average Trading Volume: 86,166 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.38 (99.5% Upside)K92 Mining Inc. engages in the mining, exploration, and development of mineral deposits in Papua New Guinea. The company produces gold, copper, and silver. The company's mineral properties include the Kainantu gold mine project that covers an area of 836.8 square kilometers located in the Eastern Highlands province of Papua New Guinea; and the Blue Lake gold-copper porphyry deposit located in the southwest of the Kora and Judd intrusion. K92 Mining Inc. is headquartered in Vancouver, Canada.#5 - Ur-EnergyNYSEAMERICAN:URGStock Price: $1.48 (+$0.01)P/E Ratio: -12.33Market Cap: $413.99 millionAverage Trading Volume: 3.19 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.76 (86.7% Upside)Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. Its flagship property is the Lost Creek project comprising a total of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyoming. The company was incorporated in 2004 and is headquartered in Littleton, Colorado.#6 - Reviva PharmaceuticalsNASDAQ:RVPHStock Price: $3.08 (-$0.07)P/E Ratio: -1.84Market Cap: $87.94 millionAverage Trading Volume: 207,826 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.75 (443.8% Upside)Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (Ad)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency#7 - Applied DigitalOTCMKTS:APLDStock Price: $4.24 (-$0.26)P/E Ratio: -8.65Market Cap: $517.47 millionAverage Trading Volume: 3.55 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.70 (246.7% Upside)Applied Digital Corporation designs, develops, and operates datacenters in North America. Its datacenters provide digital infrastructure solutions to the high-performance computing industry. The company also provides artificial intelligence cloud services, high performance computing datacenter hosting, and crypto datacenter hosting services. The company was formerly known as Applied Blockchain, Inc. and changed its name to Applied Digital Corporation in November 2022. Applied Digital Corporation is based in Dallas, Texas.#8 - ProQR TherapeuticsNASDAQ:PRQRStock Price: $2.47 (-$0.09)P/E Ratio: -6.33Market Cap: $208.27 millionAverage Trading Volume: 216,778 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.80 (53.8% Upside)ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.#9 - Man GroupOTCMKTS:MNGPFStock Price: $3.08P/E Ratio: 105.16Average Trading Volume: 1,371 sharesDividend Yield: 3.50%<Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $128.50 (4,072.1% Upside)Man Group Limited is a publicly owned investment manager. The firm provides long-only and alternative investment management services worldwide. It offers a range of liquid investment products and solutions, which include quantitative, multi-manager and discretionary investment styles, and span across various asset classes, like equity, real estate, currency, credit, volatility, and commodities. The firm distributes its products and solutions directly to institutions and to private investors through a global network of intermediaries. Man Group Limited was founded in 1783 and is based in St. Helier, Jersey with an additional office in London, United Kingdom.#10 - Gritstone bioNASDAQ:GRTSStock Price: $2.47 (+$0.09)P/E Ratio: -2.06Market Cap: $233.40 millionAverage Trading Volume: 1.71 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.50 (163.2% Upside)Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.#11 - Vor BiopharmaNYSE:VORStock Price: $1.92 (-$0.01)P/E Ratio: -1.01Market Cap: $130.87 millionAverage Trading Volume: 355,831 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.19 (691.0% Upside)Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy#12 - BitfarmsNASDAQ:BITFStock Price: $2.23 (-$0.03)P/E Ratio: -6.03Market Cap: $755.19 millionAverage Trading Volume: 28.42 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (79.4% Upside)Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. It owns and operates server farms that primarily validates transactions on the Bitcoin Blockchain and earning cryptocurrency from block rewards and transaction fees. The company also provides electrician services to commercial and residential customers in Quebec, Canada. It also undertakes hosting of third-party mining hardware. Bitfarms Ltd. was founded in 2017 and is based in Toronto, Canada.#13 - RedwireNYSE:RDWStock Price: $3.50 (+$0.15)P/E Ratio: -4.79Market Cap: $217.08 millionAverage Trading Volume: 192,448 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.25 (78.6% Upside)Redwire Corporation operates as a space infrastructure company in the United States, Netherlands, Luxemburg, the United Kingdom, Italy, Germany, Spain, South Korea, Poland, and internationally. It provides critical space solutions and reliability components for solar power generation, in-space 3D printing and manufacturing, avionics, critical components, sensors, digital engineering, and space-based biotechnology. The company's product portfolio includes antennas, boom deployers, data modules, deorbit devices, deployable radiator, engineering services and solutions, heat pipes, in-space manufacturing, power solutions, robotics software, solar arrays, space cameras, space-based research, star tracker, sensors and shades, and thermal energy storage. In addition, it offers space domain awareness and resiliency including sensor systems for on-orbit monitoring, advanced modeling & simulation, cyber resiliency, asset hardening, robotics, and full satellite solutions; and digitally engaged spacecraft technology includes software and hardware-in-the-loop configurations, to enable next generation space architectures and solutions, such as advanced artificial intelligence, machine learning, and cyber technologies. It also provides low-earth orbit commercialization, which includes in-space additive manufacturing, space-based biotechnology applications, space plant and animal science, in-space advanced material manufacturing and support of human exploration, habitation, and commercial activities in space. Redwire Corporation is headquartered in Jacksonville, Florida.#14 - Carisma TherapeuticsNASDAQ:CARMStock Price: $2.27 (-$0.05)P/E Ratio: -0.61Market Cap: $93.63 millionAverage Trading Volume: 170,640 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.00 (340.5% Upside)Carisma Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.#15 - Altus PowerNYSE:AMPSStock Price: $4.72 (+$0.15)P/E Ratio: -67.42Market Cap: $731.18 millionAverage Trading Volume: 1.16 million sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.63 (82.7% Upside)Altus Power, Inc., a clean electrification company, develops, owns, constructs, and operates roof, ground, and carport-based photovoltaic solar energy generation and storage systems. It serves commercial, industrial, public sector, and community solar customers. The company was founded in 2013 and is headquartered in Stamford, Connecticut.#16 - BioAtlaNASDAQ:BCABStock Price: $2.34 (-$0.10)P/E Ratio: -0.88Market Cap: $116.96 millionAverage Trading Volume: 318,912 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.80 (532.5% Upside)BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Make This $3 Trade the Instant the Opening Bell Rings (Ad)Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00#17 - Archer AviationNYSE:ACHRStock Price: $4.87 (-$0.15)P/E Ratio: -2.82Market Cap: $1.51 billionAverage Trading Volume: 5.58 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.60 (97.1% Upside)Archer Aviation Inc., an urban air mobility company, engages in designs, develops, manufactures, and operates electric vertical takeoff and landing aircrafts to carry passengers. The company was formerly known as Atlas Crest Investment Corp. and changed its name to Archer Aviation Inc. Archer Aviation Inc. was incorporated in 2018 and is headquartered in San Jose, California.#18 - Regulus TherapeuticsNASDAQ:RGLSStock Price: $2.36 (+$0.25)P/E Ratio: -1.48Market Cap: $42.67 millionAverage Trading Volume: 8.92 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.50 (217.8% Upside)Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.#19 - Virgin Money UKOTCMKTS:CYBBFStock Price: $2.16Average Trading Volume: 300 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AVirgin Money UK PLC provides banking products and services for consumers, and small and medium sized businesses under the Clydesdale Bank, Yorkshire Bank, and Virgin Money brands in the United Kingdom. The company offers savings and current accounts, mortgages, credit cards, and home loans; business loans, overdraft facilities, treasury solutions, and corporate and structured finance; risk management; asset and invoice finance services; international trade services; and home, car, and life and critical illness insurance products. It also offers online and mobile banking, and telephone banking services. The company was formerly known as CYBG PLC and changed its name to Virgin Money UK PLC in October 2019. Virgin Money UK PLC was founded in 1838 and is headquartered in Glasgow, the United Kingdom.#20 - Aptose BiosciencesNASDAQ:APTOStock Price: $1.50 (-$0.02)P/E Ratio: -0.19Market Cap: $23.87 millionAverage Trading Volume: 78,271 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $36.50 (2,333.3% Upside)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.#21 - Clearside BiomedicalNASDAQ:CLSDStock Price: $1.56 (-$0.15)P/E Ratio: -2.94Market Cap: $127.77 millionAverage Trading Volume: 590,896 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.75 (204.5% Upside)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.#22 - TeraWulfNASDAQ:WULFStock Price: $1.73 (-$0.05)Market Cap: $428.83 millionAverage Trading Volume: 18.40 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.65 (111.0% Upside)TeraWulf Inc., together with its subsidiaries, operates as a digital asset technology company in the United States. It develops, owns, and operates bitcoin mining facility sites in New York and Pennsylvania. TeraWulf Inc. was founded in 2021 and is based in Easton, Maryland.#23 - Checkpoint TherapeuticsNASDAQ:CKPTStock Price: $1.89 (-$0.03)Market Cap: $45.17 millionAverage Trading Volume: 401,439 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $22.60 (1,095.8% Upside)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.#24 - Taysha Gene TherapiesNASDAQ:TSHAStock Price: $2.13 (-$0.17)P/E Ratio: -0.83Market Cap: $430.01 millionAverage Trading Volume: 3.08 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.71 (168.3% Upside)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.#25 - Unicycive TherapeuticsNASDAQ:UNCYStock Price: $1.43 (-$0.03)P/E Ratio: -0.82Market Cap: $50.74 millionAverage Trading Volume: 483,921 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.30 (480.4% Upside)Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Insider Selling of Amazon Spikes in Q1, but it's Not Time to Sell Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off 2 Dollar Stores Taking Different Paths to Profitability S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback? MarketBeat Week in Review – 3/11 – 3/15 These 3 Stocks Just Entered Overbought Territory Adobe Stock Reaches Turning Point as Market Outlook Resets Analysts Lead These Markets: The Most Upgraded Stocks in Q1 Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.